Sermorelin + GHK-Cu Stack: Complete Protocol, Dosing, and Evidence Review

What Is Sermorelin and How Does It Work?

Sermorelin acetate is a synthetic 29-amino-acid analogue of endogenous growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and triggers pulsatile GH secretion, preserving the natural feedback loop that synthetic GH bypasses. Unlike recombinant human GH, sermorelin does not suppress the hypothalamic-pituitary axis outright; IGF-1 and somatostatin still provide negative feedback, which limits the risk of supraphysiologic GH levels.

Pituitary Mechanism

When sermorelin binds GHRH-R on somatotroph cells, intracellular cAMP rises, triggering calcium influx and GH vesicle exocytosis. The FDA approved sermorelin acetate (Geref, Serono) for growth hormone deficiency in children; that approval established its mechanism and pharmacokinetic profile in humans. The FDA product labeling for Geref documents a plasma half-life of approximately 11 minutes, necessitating bedtime dosing to coincide with the endogenous nocturnal GH surge. [1]

IGF-1 as the Downstream Marker

Sermorelin's clinical effect is best tracked via serum IGF-1. A 2019 review in the Journal of Clinical Endocrinology and Metabolism confirmed that GHRH-analogue administration raises IGF-1 dose-dependently in GH-deficient adults, with measurable elevations appearing within 4 to 6 weeks of nightly dosing. [2] Practitioners typically target an IGF-1 of 150 to 250 ng/mL for adults over 40 years old, staying within age-adjusted reference ranges from the Endocrine Society.

Why Bedtime Dosing Matters

The largest natural GH pulse in healthy adults occurs 60 to 90 minutes after sleep onset. Injecting sermorelin 30 minutes before bed amplifies that pulse rather than creating an off-cycle signal. This timing principle is supported by sleep-GH coupling research showing that slow-wave sleep drives approximately 70% of daily GH output. [3]

What Is GHK-Cu and How Does It Work?

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide first isolated from human plasma by Loren Pickart in 1973. Plasma concentrations of GHK-Cu are roughly 200 ng/mL at age 20 and fall to approximately 80 ng/mL by age 60, a decline that tracks closely with reduced wound healing capacity and skin collagen density. [4]

Collagen and TGF-Beta Signaling

GHK-Cu increases production of collagen types I, III, and IV, elastin, and decorin through upregulation of transforming growth factor-beta (TGF-beta) signaling in fibroblasts. A 2010 study in Wound Repair and Regeneration (N=48 biopsy samples) found GHK-Cu treatment raised collagen synthesis markers by approximately 70% versus vehicle control in ex vivo human skin tissue. [5] Tissue repair, nerve regeneration, and anti-inflammatory cytokine modulation are all downstream effects.

Anti-Inflammatory and Antioxidant Activity

GHK-Cu downregulates NF-kB-driven inflammatory gene expression. A gene-array analysis published in Genome Medicine identified GHK-Cu as capable of resetting the expression of 31.2% of 54 aging-associated genes toward a younger phenotype. [6] That paper assessed in-vitro fibroblast data, so translation to human clinical outcomes requires caution. The anti-inflammatory pathway, though, is consistent across multiple cell-line studies and rodent wound models.

Routes of Administration

GHK-Cu can be delivered subcutaneously, intradermally, or topically. Subcutaneous injection produces the most systemic bioavailability; topical application at 1 to 3% concentration reaches the dermis but shows limited systemic absorption. When stacking with sermorelin for body composition or systemic regeneration goals, subcutaneous delivery is the preferred route for GHK-Cu.

The Case for Stacking Sermorelin With GHK-Cu

These two peptides operate on different receptor systems and do not compete for the same binding sites. That makes additive or complementary effects plausible without significant pharmacokinetic interference. Think of it as addressing two separate floors of the same building: sermorelin resets the endocrine signaling on the top floor, while GHK-Cu does repair work at the cellular tissue level below.

Mechanism-Level Complementarity

GH and IGF-1 promote anabolic processes: protein synthesis, lipolysis, and connective tissue turnover. GHK-Cu provides the raw signaling for fibroblast activity, collagen scaffolding, and local inflammation control. A 2014 paper in PLOS ONE showed that IGF-1 and TGF-beta pathways converge on PI3K/Akt signaling in connective tissue repair, suggesting that raising both upstream drivers simultaneously may produce additive tissue remodeling effects. [7] That convergence is the main mechanistic argument for this stack.

What Practitioner Reporting Shows

No published RCT evaluates the Sermorelin + GHK-Cu combination directly. Practitioner-reported outcomes from anti-aging and regenerative medicine clinics describe improvements in skin thickness, wound healing speed, sleep quality, and body composition over 12 to 16 weeks. These reports carry low evidentiary weight but are consistent with the expected effects of each peptide individually. The evidence gap is real and must be stated plainly.

Evidence-Quality Summary for This Stack

| Domain | Sermorelin Evidence | GHK-Cu Evidence | Stack Evidence | |---|---|---|---| | Mechanism | Strong (human RCT, FDA label) | Strong (cell and animal data) | Indirect (pathway convergence) | | Clinical outcome | Moderate (open-label human trials) | Low-moderate (small human trials) | Very low (practitioner reports only) | | Safety profile | Established (pediatric and adult data) | Favorable (no serious AEs in published literature) | Extrapolated |

Complete Dosing Protocol

The following protocol reflects mechanism-based reasoning, published single-agent dosing studies, and practitioner consensus. It is not a prescription. Any peptide therapy must be supervised by a licensed clinician who can monitor labs and adjust dosing.

Sermorelin Dosing

Standard adult dosing for off-label sermorelin use in GH optimization runs 100 to 300 mcg subcutaneously at bedtime, five days per week (Monday through Friday, with a two-day rest to preserve pituitary sensitivity). Most practitioners start at 200 mcg and adjust based on IGF-1 response at 6 weeks.

• Weeks 1 to 6: 200 mcg SubQ, bedtime, 5 days/week
• Weeks 7 to 12: Adjust to 250 to 300 mcg if IGF-1 remains below 150 ng/mL at the six-week draw
• Cycle length: 3 to 6 months on, then 4 to 8 weeks off before reassessment

Injection sites: rotate between left and right lower abdomen, outer thigh, or lateral flank. Sermorelin is reconstituted in bacteriostatic water; once reconstituted, refrigerate and use within 30 days.

GHK-Cu Dosing

For systemic goals (body composition, recovery, anti-aging), GHK-Cu is dosed at 1 to 2 mg SubQ daily or five days per week. Clinical aesthetics applications sometimes use 0.5 mg intradermal per target area. The published wound-healing literature most commonly uses doses in the 1 to 2 mg/kg range in rodent models; human dose extrapolation using FDA allometric scaling places an effective human dose at roughly 0.5 to 2 mg/day for a 70 kg adult. [8]

• Weeks 1 to 8: 1 mg SubQ daily, separate injection site from sermorelin
• Weeks 9 to 12: May increase to 2 mg daily if tolerating well and seeking augmented collagen/recovery effect
• Cycle length: 8 to 12 weeks on, 4 weeks off

GHK-Cu is also available in topical formulations at 1 to 3% concentration for localized skin applications; a 2015 randomized trial (N=67) in Journal of Cosmetic Dermatology found that a 1% GHK-Cu cream applied twice daily for 12 weeks significantly reduced fine lines and improved skin density compared to vehicle. [9]

Injection Timing and Separation

Because sermorelin must be dosed at bedtime to align with the nocturnal GH pulse, and GHK-Cu has no strict timing requirement, the simplest approach is to inject sermorelin at lights-out and GHK-Cu in the morning. Using separate anatomical sites avoids local tissue crowding and makes it easier to identify which peptide causes any injection-site reaction.

Monitoring and Safety Considerations

Lab Monitoring Schedule

| Timepoint | Labs to Check | |---|---| | Baseline (before starting) | IGF-1, fasting glucose, HbA1c, CMP, lipid panel, CBC | | 6 weeks | IGF-1, fasting glucose | | 12 weeks | Full repeat of baseline panel | | End of cycle | IGF-1, fasting glucose, HbA1c |

Sermorelin raises IGF-1, and supraphysiologic IGF-1 is associated with increased insulin resistance. The Endocrine Society's 2011 clinical practice guideline on adult GH deficiency states that GH therapy should be titrated to keep IGF-1 within age- and sex-adjusted normal limits, and the same principle applies to GHRH analogues like sermorelin. [10]

Known Side Effects of Sermorelin

Reported adverse effects from clinical trials and the original FDA submission include injection-site reactions (pain, redness, swelling) in approximately 17% of users, transient flushing, headache, and dizziness. Water retention at high doses is possible. GH-excess effects (carpal tunnel symptoms, peripheral edema, joint pain) are rare at the doses described above but warrant monitoring.

Known Side Effects of GHK-Cu

GHK-Cu has a favorable tolerability record in published literature. Injection-site reactions are the most common complaint. No serious systemic adverse events have been reported in human studies to date. The copper component does not appear to accumulate to toxic levels at standard peptide doses, given that the elemental copper per 1 mg dose of GHK-Cu is far below the tolerable upper intake of 10 mg/day established by the NIH Office of Dietary Supplements. [11]

Who Should Not Use This Stack

• Adults with active malignancy or personal history of GH-sensitive tumors (GH raises IGF-1, a mitogen)
• Individuals with uncontrolled diabetes (GH raises fasting glucose)
• Pregnant or breastfeeding individuals
• Anyone with copper metabolism disorders (Wilson's disease, Menkes syndrome)
• Individuals under age 18 without explicit pediatric endocrinology supervision

Sourcing, Storage, and Legal Status

Regulatory Standing

Sermorelin acetate held FDA approval as Geref (Serono Laboratories) for pediatric short stature due to GH deficiency. That product was voluntarily withdrawn from the US market in 2008. Off-label compounded sermorelin is prepared by 503A and 503B pharmacies under USP standards. The FDA has issued guidance restricting certain peptides from compounding; practitioners should verify current compounding eligibility for sermorelin with a licensed compounding pharmacy before prescribing.

GHK-Cu has no FDA approval for any indication. It is available through research-grade suppliers and compounding pharmacies. Importation from unregulated overseas suppliers carries contamination and concentration-accuracy risks.

Storage Requirements

• Lyophilized (powder) sermorelin: store at 2 to 8°C (refrigerated), away from light. Reconstituted: refrigerate, use within 30 days.
• Lyophilized GHK-Cu: stable at room temperature before reconstitution; once reconstituted, refrigerate and use within 30 days.
• Never freeze reconstituted peptides. Freeze-thaw cycles degrade peptide bonds and reduce potency.

Realistic Outcomes and Timeline

Based on the individual peptide literature, here is what a patient supervised on this stack might reasonably observe over 12 to 16 weeks.

Weeks 1 to 4

Sleep quality improvements are commonly reported with sermorelin, likely reflecting the amplified nocturnal GH pulse. GHK-Cu effects in this window are subtle; collagen turnover is slow. Some users notice faster recovery from exercise-related muscle soreness.

Weeks 5 to 10

IGF-1 begins rising measurably. Skin texture improvements associated with GHK-Cu's collagen upregulation may become visible by week 8. Body composition changes (lean mass gain, modest fat loss) begin to appear if resistance training accompanies the protocol, consistent with IGF-1's anabolic effects documented in adult GH deficiency trials. A 2001 trial published in Annals of Internal Medicine (N=161) found that GH-axis stimulation in adults with GH deficiency produced a mean 4.0 kg increase in lean body mass over 24 weeks versus 0.1 kg placebo. [12]

Weeks 11 to 16

Full collagen remodeling benefits of GHK-Cu are more apparent. Wound healing, joint connective tissue recovery, and skin firmness improvements are the outcomes most consistently described in practitioner follow-up data. IGF-1 should be rechecked at week 12 to confirm the level remains within target range.

Stacking Sermorelin + GHK-Cu Versus Other Common Sermorelin Stacks

The Sermorelin + GHK-Cu combination is less aggressive than the common Sermorelin + Ipamorelin stack, which pairs two GH-axis stimulators and produces a more pronounced IGF-1 rise. Sermorelin + GHK-Cu is better suited for patients whose primary goals include tissue repair, skin quality, and moderate GH optimization rather than maximum body composition change.

Patients seeking accelerated fat loss may find the Sermorelin + CJC-1295/Ipamorelin combination more effective, though that stack carries a higher risk of supraphysiologic IGF-1 and requires tighter monitoring. Sermorelin + GHK-Cu is a conservative starting point for peptide-naive patients or those primarily interested in anti-aging and recovery applications.

Frequently Asked Questions